A recent update on the use of microbial transglutaminase for the generation of biotherapeutics(183 views) Doti N, Caporale A, Monti A, Sandomenico A, Selis F, Ruvo M
World J Microbiol Biotechnol (ISSN: 0959-3993linking), 2020 Mar 14; 36(4): 53-53.
Institute of Biostructure and Bioimaging, CNR (IBB-CNR), Via Mezzocannone, 16, 80134, Naples, Italy. nunzianna.doti@cnr.it.
Institute of Crystallography, CNR (IC-CNR), c/o Area Science Park s.s. 14 Km 163.5, Basovizza, 34149, Trieste, Italy.
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABIF), University L. Vanvitelli, Via Vivaldi, 43, 80100, Caserta, Italy.
BioVIIIx R&D, Via B. Brin, 59C, 80142, Naples, Italy.
References: Not available.
A recent update on the use of microbial transglutaminase for the generation of biotherapeutics
The recent scientific progresses on the use of enzyme-mediated reactions in organic, non-aqueous and aqueous media have significantly supported the growing demand of new biotechnological and/or pharmacological products. Today, a plethora of microbial enzymes, used as biocatalysts, are available. Among these, microbial transglutaminases (MTGs) are broadly used for their ability to catalyse the formation of an isopeptide bond between the γ-amide group of glutamines and the ε-amino group of lysine. Due to their promiscuity towards primary amine-containing substrates and the more stringent specificity for glutamine-containing peptide sequences, several combined approaches can be tailored for different settings, making MTGs very attractive catalysts for generating protein-protein and protein small molecule's conjugates. The present review offers a recent update on the modifications attainable by MTG-catalysed bioreactions as reported between 2014 and 2019. In particular, we present a detailed and comparative overview on the MTG-based methods for proteins and antibodies engineering, with a particular outlook on the synthesis of homogeneous antibody-drug conjugates.
A recent update on the use of microbial transglutaminase for the generation of biotherapeutics